Health · 1 sources covering this

Trump uses ‘contested’ power to cut more funding to HHS

Late Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting several HHS programs focused on immigrants and diversity

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
Trump uses ‘contested’ power to cut more funding to HHS
Late Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting several HHS programs focused on immigrants and diversity
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/ce3980bf463c3b833030f84351303f12d2b88332"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Trump uses ‘contested’ power to cut more funding to HHS"></iframe>

Trump uses ‘contested’ power to cut more funding to HHS

How 1 sources are covering this

Trump uses ‘contested’ power to cut more funding to HHS

More from Health

STAT+: AbbVie wins FDA nod for Parkinson’s pill

STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

5 tips for parents worried about their kids' screen time and online safety

Food Safety Finds a Place Among ‘Kitchen-Table’ Political Issues

Reader

Trust & legal

Across the network

How 1 sources are covering this

Trump uses ‘contested’ power to cut more funding to HHS

More from Health

STAT+: AbbVie wins FDA nod for Parkinson&#8217;s pill

STAT+: Pharmalittle: We&#8217;re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

5 tips for parents worried about their kids' screen time and online safety

Food Safety Finds a Place Among ‘Kitchen-Table’ Political Issues

Reader

Trust & legal

Across the network

STAT+: AbbVie wins FDA nod for Parkinson’s pill

STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more